nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—ABCG2—Vismodegib—skin cancer	0.061	0.138	CbGbCtD
Dasatinib—ABCG2—Vemurafenib—skin cancer	0.0482	0.109	CbGbCtD
Dasatinib—CYP1A2—Imiquimod—skin cancer	0.0363	0.082	CbGbCtD
Dasatinib—CYP1B1—Docetaxel—skin cancer	0.0348	0.0786	CbGbCtD
Dasatinib—CYP1A1—Dacarbazine—skin cancer	0.0341	0.0771	CbGbCtD
Dasatinib—ABCG2—Dactinomycin—skin cancer	0.0321	0.0724	CbGbCtD
Dasatinib—ABCB1—Vismodegib—skin cancer	0.022	0.0497	CbGbCtD
Dasatinib—ABCG2—Fluorouracil—skin cancer	0.0217	0.049	CbGbCtD
Dasatinib—CYP1A2—Vemurafenib—skin cancer	0.0199	0.0449	CbGbCtD
Dasatinib—CYP3A4—Imiquimod—skin cancer	0.019	0.043	CbGbCtD
Dasatinib—CYP3A4—Temozolomide—skin cancer	0.019	0.043	CbGbCtD
Dasatinib—ABCG2—Docetaxel—skin cancer	0.0166	0.0374	CbGbCtD
Dasatinib—CYP1A2—Dacarbazine—skin cancer	0.0152	0.0344	CbGbCtD
Dasatinib—CYP3A4—Vismodegib—skin cancer	0.0132	0.0298	CbGbCtD
Dasatinib—ABCB1—Dactinomycin—skin cancer	0.0116	0.0261	CbGbCtD
Dasatinib—CYP3A4—Vemurafenib—skin cancer	0.0104	0.0235	CbGbCtD
Dasatinib—CYP3A5—Docetaxel—skin cancer	0.00917	0.0207	CbGbCtD
Dasatinib—CYP1A2—Fluorouracil—skin cancer	0.00894	0.0202	CbGbCtD
Dasatinib—ABCB1—Docetaxel—skin cancer	0.00597	0.0135	CbGbCtD
Dasatinib—CYP3A4—Docetaxel—skin cancer	0.00358	0.00808	CbGbCtD
Dasatinib—FYN—nipple—skin cancer	0.000679	0.00432	CbGeAlD
Dasatinib—STAT5B—lymphoid tissue—skin cancer	0.000677	0.00431	CbGeAlD
Dasatinib—KIT—blood vessel—skin cancer	0.000664	0.00423	CbGeAlD
Dasatinib—MAP3K3—nipple—skin cancer	0.000663	0.00422	CbGeAlD
Dasatinib—MAP4K5—nipple—skin cancer	0.000663	0.00422	CbGeAlD
Dasatinib—TEC—lymph node—skin cancer	0.000654	0.00416	CbGeAlD
Dasatinib—STAT5B—female reproductive system—skin cancer	0.000653	0.00416	CbGeAlD
Dasatinib—PDGFRB—blood vessel—skin cancer	0.000649	0.00413	CbGeAlD
Dasatinib—SIK2—head—skin cancer	0.000647	0.00412	CbGeAlD
Dasatinib—ZAK—mammalian vulva—skin cancer	0.000637	0.00406	CbGeAlD
Dasatinib—EPHB6—nipple—skin cancer	0.000634	0.00403	CbGeAlD
Dasatinib—PKMYT1—head—skin cancer	0.000631	0.00401	CbGeAlD
Dasatinib—CSK—connective tissue—skin cancer	0.000627	0.00399	CbGeAlD
Dasatinib—YES1—nipple—skin cancer	0.000612	0.0039	CbGeAlD
Dasatinib—BTK—mammalian vulva—skin cancer	0.000608	0.00387	CbGeAlD
Dasatinib—EPHB2—head—skin cancer	0.000601	0.00383	CbGeAlD
Dasatinib—SRMS—head—skin cancer	0.000589	0.00375	CbGeAlD
Dasatinib—SIK3—female reproductive system—skin cancer	0.000587	0.00374	CbGeAlD
Dasatinib—TXK—head—skin cancer	0.000583	0.00371	CbGeAlD
Dasatinib—RIPK2—connective tissue—skin cancer	0.000582	0.0037	CbGeAlD
Dasatinib—EPHA8—head—skin cancer	0.000577	0.00367	CbGeAlD
Dasatinib—STK35—skin of body—skin cancer	0.00057	0.00363	CbGeAlD
Dasatinib—SIK1—connective tissue—skin cancer	0.000568	0.00362	CbGeAlD
Dasatinib—CSK—skin of body—skin cancer	0.000566	0.0036	CbGeAlD
Dasatinib—ZAK—lymphoid tissue—skin cancer	0.000566	0.0036	CbGeAlD
Dasatinib—TESK1—mammalian vulva—skin cancer	0.000563	0.00359	CbGeAlD
Dasatinib—ERBB3—connective tissue—skin cancer	0.000557	0.00354	CbGeAlD
Dasatinib—STK36—mammalian vulva—skin cancer	0.000554	0.00353	CbGeAlD
Dasatinib—EPHB3—mammalian vulva—skin cancer	0.000554	0.00353	CbGeAlD
Dasatinib—RIPK2—epithelium—skin cancer	0.000552	0.00352	CbGeAlD
Dasatinib—MAP3K2—connective tissue—skin cancer	0.000551	0.00351	CbGeAlD
Dasatinib—LYN—lymphoid tissue—skin cancer	0.000551	0.00351	CbGeAlD
Dasatinib—ZAK—female reproductive system—skin cancer	0.000546	0.00347	CbGeAlD
Dasatinib—STAT5B—head—skin cancer	0.000545	0.00347	CbGeAlD
Dasatinib—MAP2K5—nipple—skin cancer	0.000542	0.00345	CbGeAlD
Dasatinib—BTK—lymphoid tissue—skin cancer	0.00054	0.00344	CbGeAlD
Dasatinib—LIMK2—mammalian vulva—skin cancer	0.000536	0.00341	CbGeAlD
Dasatinib—CSF1R—nipple—skin cancer	0.000529	0.00337	CbGeAlD
Dasatinib—ERBB3—epithelium—skin cancer	0.000528	0.00336	CbGeAlD
Dasatinib—RIPK2—skin of body—skin cancer	0.000525	0.00334	CbGeAlD
Dasatinib—MAP3K19—female reproductive system—skin cancer	0.000523	0.00333	CbGeAlD
Dasatinib—BMPR1B—female reproductive system—skin cancer	0.000523	0.00333	CbGeAlD
Dasatinib—CYP1B1—hair follicle—skin cancer	0.000522	0.00332	CbGeAlD
Dasatinib—MAPK14—connective tissue—skin cancer	0.000518	0.0033	CbGeAlD
Dasatinib—CYP1A1—skin epidermis—skin cancer	0.000517	0.00329	CbGeAlD
Dasatinib—CSK—mammalian vulva—skin cancer	0.000516	0.00329	CbGeAlD
Dasatinib—TNK2—female reproductive system—skin cancer	0.000513	0.00327	CbGeAlD
Dasatinib—EPHB1—lymph node—skin cancer	0.000513	0.00327	CbGeAlD
Dasatinib—SIK1—skin of body—skin cancer	0.000513	0.00327	CbGeAlD
Dasatinib—HCK—mammalian vulva—skin cancer	0.000509	0.00324	CbGeAlD
Dasatinib—EPHA3—head—skin cancer	0.000504	0.00321	CbGeAlD
Dasatinib—ERBB3—skin of body—skin cancer	0.000503	0.0032	CbGeAlD
Dasatinib—MAPK14—epithelium—skin cancer	0.000492	0.00313	CbGeAlD
Dasatinib—EPHB4—connective tissue—skin cancer	0.000491	0.00313	CbGeAlD
Dasatinib—SIK3—head—skin cancer	0.00049	0.00312	CbGeAlD
Dasatinib—JAK2—connective tissue—skin cancer	0.000488	0.00311	CbGeAlD
Dasatinib—TESK1—female reproductive system—skin cancer	0.000482	0.00307	CbGeAlD
Dasatinib—FYN—connective tissue—skin cancer	0.000481	0.00306	CbGeAlD
Dasatinib—KIT—nipple—skin cancer	0.00048	0.00306	CbGeAlD
Dasatinib—LIMK2—lymphoid tissue—skin cancer	0.000476	0.00303	CbGeAlD
Dasatinib—KIT—neck—skin cancer	0.000475	0.00303	CbGeAlD
Dasatinib—STK36—female reproductive system—skin cancer	0.000475	0.00302	CbGeAlD
Dasatinib—EPHB3—female reproductive system—skin cancer	0.000475	0.00302	CbGeAlD
Dasatinib—PDGFRB—nipple—skin cancer	0.000469	0.00299	CbGeAlD
Dasatinib—MAPK14—skin of body—skin cancer	0.000468	0.00298	CbGeAlD
Dasatinib—SIK1—mammalian vulva—skin cancer	0.000468	0.00298	CbGeAlD
Dasatinib—EPHB4—epithelium—skin cancer	0.000466	0.00297	CbGeAlD
Dasatinib—PDGFRB—neck—skin cancer	0.000464	0.00296	CbGeAlD
Dasatinib—JAK2—epithelium—skin cancer	0.000463	0.00295	CbGeAlD
Dasatinib—EPHA4—mammalian vulva—skin cancer	0.000463	0.00295	CbGeAlD
Dasatinib—LIMK2—female reproductive system—skin cancer	0.000459	0.00292	CbGeAlD
Dasatinib—CSK—lymphoid tissue—skin cancer	0.000458	0.00292	CbGeAlD
Dasatinib—EPHA2—epithelium—skin cancer	0.000458	0.00291	CbGeAlD
Dasatinib—ZAK—head—skin cancer	0.000456	0.0029	CbGeAlD
Dasatinib—HCK—lymphoid tissue—skin cancer	0.000452	0.00288	CbGeAlD
Dasatinib—EPHA5—head—skin cancer	0.000446	0.00284	CbGeAlD
Dasatinib—STK35—female reproductive system—skin cancer	0.000445	0.00283	CbGeAlD
Dasatinib—LYN—head—skin cancer	0.000444	0.00283	CbGeAlD
Dasatinib—CSK—female reproductive system—skin cancer	0.000442	0.00281	CbGeAlD
Dasatinib—JAK2—skin of body—skin cancer	0.000441	0.00281	CbGeAlD
Dasatinib—MAP3K19—head—skin cancer	0.000437	0.00278	CbGeAlD
Dasatinib—BMPR1B—head—skin cancer	0.000437	0.00278	CbGeAlD
Dasatinib—FYN—skin of body—skin cancer	0.000435	0.00277	CbGeAlD
Dasatinib—YES1—connective tissue—skin cancer	0.000434	0.00277	CbGeAlD
Dasatinib—BMX—lymph node—skin cancer	0.000431	0.00274	CbGeAlD
Dasatinib—TNK2—head—skin cancer	0.000429	0.00273	CbGeAlD
Dasatinib—PDGFRA—connective tissue—skin cancer	0.000426	0.00271	CbGeAlD
Dasatinib—BLK—lymph node—skin cancer	0.000426	0.00271	CbGeAlD
Dasatinib—FGR—mammalian vulva—skin cancer	0.000425	0.00271	CbGeAlD
Dasatinib—LCK—mammalian vulva—skin cancer	0.000425	0.00271	CbGeAlD
Dasatinib—MAP3K3—skin of body—skin cancer	0.000425	0.0027	CbGeAlD
Dasatinib—ABL1—nipple—skin cancer	0.000418	0.00266	CbGeAlD
Dasatinib—SRC—connective tissue—skin cancer	0.000418	0.00266	CbGeAlD
Dasatinib—SIK1—lymphoid tissue—skin cancer	0.000415	0.00264	CbGeAlD
Dasatinib—FMO3—mammalian vulva—skin cancer	0.000411	0.00261	CbGeAlD
Dasatinib—RIPK2—female reproductive system—skin cancer	0.00041	0.00261	CbGeAlD
Dasatinib—TXK—lymph node—skin cancer	0.000408	0.0026	CbGeAlD
Dasatinib—ERBB3—lymphoid tissue—skin cancer	0.000407	0.00259	CbGeAlD
Dasatinib—EPHB6—skin of body—skin cancer	0.000406	0.00258	CbGeAlD
Dasatinib—EPHB4—mammalian vulva—skin cancer	0.000405	0.00258	CbGeAlD
Dasatinib—MAP3K2—lymphoid tissue—skin cancer	0.000403	0.00257	CbGeAlD
Dasatinib—TESK1—head—skin cancer	0.000403	0.00257	CbGeAlD
Dasatinib—JAK2—mammalian vulva—skin cancer	0.000402	0.00256	CbGeAlD
Dasatinib—SIK1—female reproductive system—skin cancer	0.0004	0.00255	CbGeAlD
Dasatinib—EPHA2—mammalian vulva—skin cancer	0.000397	0.00253	CbGeAlD
Dasatinib—SRC—epithelium—skin cancer	0.000397	0.00253	CbGeAlD
Dasatinib—STK36—head—skin cancer	0.000397	0.00253	CbGeAlD
Dasatinib—EPHB3—head—skin cancer	0.000397	0.00253	CbGeAlD
Dasatinib—EPHA4—female reproductive system—skin cancer	0.000396	0.00252	CbGeAlD
Dasatinib—FYN—mammalian vulva—skin cancer	0.000396	0.00252	CbGeAlD
Dasatinib—ERBB3—female reproductive system—skin cancer	0.000393	0.0025	CbGeAlD
Dasatinib—MAP3K2—female reproductive system—skin cancer	0.000389	0.00248	CbGeAlD
Dasatinib—MAP3K3—mammalian vulva—skin cancer	0.000387	0.00247	CbGeAlD
Dasatinib—MAP4K5—mammalian vulva—skin cancer	0.000387	0.00247	CbGeAlD
Dasatinib—LIMK2—head—skin cancer	0.000383	0.00244	CbGeAlD
Dasatinib—STAT5B—lymph node—skin cancer	0.000382	0.00243	CbGeAlD
Dasatinib—MAPK14—lymphoid tissue—skin cancer	0.000379	0.00241	CbGeAlD
Dasatinib—FGR—lymphoid tissue—skin cancer	0.000377	0.0024	CbGeAlD
Dasatinib—SRC—skin of body—skin cancer	0.000377	0.0024	CbGeAlD
Dasatinib—CSF1R—connective tissue—skin cancer	0.000375	0.00239	CbGeAlD
Dasatinib—STK35—head—skin cancer	0.000372	0.00237	CbGeAlD
Dasatinib—EPHB6—mammalian vulva—skin cancer	0.00037	0.00236	CbGeAlD
Dasatinib—CSK—head—skin cancer	0.000369	0.00235	CbGeAlD
Dasatinib—MAPK14—female reproductive system—skin cancer	0.000366	0.00233	CbGeAlD
Dasatinib—HCK—head—skin cancer	0.000364	0.00232	CbGeAlD
Dasatinib—FGR—female reproductive system—skin cancer	0.000364	0.00232	CbGeAlD
Dasatinib—YES1—mammalian vulva—skin cancer	0.000358	0.00228	CbGeAlD
Dasatinib—JAK2—lymphoid tissue—skin cancer	0.000357	0.00227	CbGeAlD
Dasatinib—EPHA3—lymph node—skin cancer	0.000353	0.00225	CbGeAlD
Dasatinib—EPHA2—lymphoid tissue—skin cancer	0.000352	0.00224	CbGeAlD
Dasatinib—FYN—lymphoid tissue—skin cancer	0.000352	0.00224	CbGeAlD
Dasatinib—EPHB4—female reproductive system—skin cancer	0.000347	0.00221	CbGeAlD
Dasatinib—JAK2—female reproductive system—skin cancer	0.000344	0.00219	CbGeAlD
Dasatinib—MAP4K5—lymphoid tissue—skin cancer	0.000344	0.00219	CbGeAlD
Dasatinib—SIK3—lymph node—skin cancer	0.000343	0.00219	CbGeAlD
Dasatinib—RIPK2—head—skin cancer	0.000343	0.00218	CbGeAlD
Dasatinib—KIT—connective tissue—skin cancer	0.000341	0.00217	CbGeAlD
Dasatinib—EPHA2—female reproductive system—skin cancer	0.00034	0.00216	CbGeAlD
Dasatinib—FYN—female reproductive system—skin cancer	0.000339	0.00216	CbGeAlD
Dasatinib—CSF1R—skin of body—skin cancer	0.000339	0.00216	CbGeAlD
Dasatinib—SIK1—head—skin cancer	0.000335	0.00213	CbGeAlD
Dasatinib—PDGFRB—connective tissue—skin cancer	0.000333	0.00212	CbGeAlD
Dasatinib—MAP4K5—female reproductive system—skin cancer	0.000332	0.00211	CbGeAlD
Dasatinib—MAP3K3—female reproductive system—skin cancer	0.000332	0.00211	CbGeAlD
Dasatinib—EPHA4—head—skin cancer	0.000331	0.00211	CbGeAlD
Dasatinib—ERBB3—head—skin cancer	0.000328	0.00209	CbGeAlD
Dasatinib—MAP3K2—head—skin cancer	0.000325	0.00207	CbGeAlD
Dasatinib—KIT—epithelium—skin cancer	0.000323	0.00206	CbGeAlD
Dasatinib—ZAK—lymph node—skin cancer	0.000319	0.00203	CbGeAlD
Dasatinib—YES1—lymphoid tissue—skin cancer	0.000318	0.00202	CbGeAlD
Dasatinib—MAP2K5—mammalian vulva—skin cancer	0.000316	0.00202	CbGeAlD
Dasatinib—PDGFRB—epithelium—skin cancer	0.000316	0.00201	CbGeAlD
Dasatinib—PDGFRA—lymphoid tissue—skin cancer	0.000312	0.00198	CbGeAlD
Dasatinib—CSF1R—mammalian vulva—skin cancer	0.000309	0.00197	CbGeAlD
Dasatinib—KIT—skin of body—skin cancer	0.000308	0.00196	CbGeAlD
Dasatinib—YES1—female reproductive system—skin cancer	0.000306	0.00195	CbGeAlD
Dasatinib—BMPR1B—lymph node—skin cancer	0.000306	0.00195	CbGeAlD
Dasatinib—SRC—lymphoid tissue—skin cancer	0.000305	0.00195	CbGeAlD
Dasatinib—MAPK14—head—skin cancer	0.000305	0.00194	CbGeAlD
Dasatinib—BTK—lymph node—skin cancer	0.000305	0.00194	CbGeAlD
Dasatinib—FGR—head—skin cancer	0.000304	0.00194	CbGeAlD
Dasatinib—PDGFRA—female reproductive system—skin cancer	0.0003	0.00191	CbGeAlD
Dasatinib—PDGFRB—skin of body—skin cancer	0.0003	0.00191	CbGeAlD
Dasatinib—TNK2—lymph node—skin cancer	0.0003	0.00191	CbGeAlD
Dasatinib—ABL1—connective tissue—skin cancer	0.000296	0.00189	CbGeAlD
Dasatinib—SRC—female reproductive system—skin cancer	0.000295	0.00188	CbGeAlD
Dasatinib—FMO3—head—skin cancer	0.000294	0.00187	CbGeAlD
Dasatinib—JAK2—head—skin cancer	0.000287	0.00183	CbGeAlD
Dasatinib—EPHA2—head—skin cancer	0.000284	0.00181	CbGeAlD
Dasatinib—FYN—head—skin cancer	0.000284	0.00181	CbGeAlD
Dasatinib—TESK1—lymph node—skin cancer	0.000282	0.0018	CbGeAlD
Dasatinib—KIT—mammalian vulva—skin cancer	0.00028	0.00179	CbGeAlD
Dasatinib—STK36—lymph node—skin cancer	0.000278	0.00177	CbGeAlD
Dasatinib—EPHB3—lymph node—skin cancer	0.000278	0.00177	CbGeAlD
Dasatinib—MAP3K3—head—skin cancer	0.000277	0.00176	CbGeAlD
Dasatinib—MAP4K5—head—skin cancer	0.000277	0.00176	CbGeAlD
Dasatinib—CSF1R—lymphoid tissue—skin cancer	0.000274	0.00175	CbGeAlD
Dasatinib—PDGFRB—mammalian vulva—skin cancer	0.000274	0.00174	CbGeAlD
Dasatinib—MAP2K5—female reproductive system—skin cancer	0.000271	0.00173	CbGeAlD
Dasatinib—LIMK2—lymph node—skin cancer	0.000268	0.00171	CbGeAlD
Dasatinib—ABL1—skin of body—skin cancer	0.000268	0.0017	CbGeAlD
Dasatinib—EPHB6—head—skin cancer	0.000265	0.00169	CbGeAlD
Dasatinib—CSF1R—female reproductive system—skin cancer	0.000265	0.00168	CbGeAlD
Dasatinib—STK35—lymph node—skin cancer	0.00026	0.00166	CbGeAlD
Dasatinib—CSK—lymph node—skin cancer	0.000258	0.00165	CbGeAlD
Dasatinib—YES1—head—skin cancer	0.000256	0.00163	CbGeAlD
Dasatinib—HCK—lymph node—skin cancer	0.000255	0.00162	CbGeAlD
Dasatinib—CYP1A2—nipple—skin cancer	0.000254	0.00162	CbGeAlD
Dasatinib—ABL2—lymph node—skin cancer	0.000254	0.00161	CbGeAlD
Dasatinib—CYP1B1—connective tissue—skin cancer	0.000251	0.0016	CbGeAlD
Dasatinib—PDGFRA—head—skin cancer	0.000251	0.0016	CbGeAlD
Dasatinib—CYP1A1—nipple—skin cancer	0.00025	0.00159	CbGeAlD
Dasatinib—KIT—lymphoid tissue—skin cancer	0.000249	0.00159	CbGeAlD
Dasatinib—SRC—head—skin cancer	0.000246	0.00157	CbGeAlD
Dasatinib—ABL1—mammalian vulva—skin cancer	0.000244	0.00155	CbGeAlD
Dasatinib—PDGFRB—lymphoid tissue—skin cancer	0.000243	0.00155	CbGeAlD
Dasatinib—KIT—female reproductive system—skin cancer	0.00024	0.00153	CbGeAlD
Dasatinib—RIPK2—lymph node—skin cancer	0.00024	0.00153	CbGeAlD
Dasatinib—PDGFRB—female reproductive system—skin cancer	0.000235	0.00149	CbGeAlD
Dasatinib—SIK1—lymph node—skin cancer	0.000234	0.00149	CbGeAlD
Dasatinib—EPHA4—lymph node—skin cancer	0.000232	0.00148	CbGeAlD
Dasatinib—ERBB3—lymph node—skin cancer	0.00023	0.00146	CbGeAlD
Dasatinib—MAP3K2—lymph node—skin cancer	0.000227	0.00145	CbGeAlD
Dasatinib—CYP1B1—skin of body—skin cancer	0.000227	0.00144	CbGeAlD
Dasatinib—MAP2K5—head—skin cancer	0.000226	0.00144	CbGeAlD
Dasatinib—CSF1R—head—skin cancer	0.000221	0.00141	CbGeAlD
Dasatinib—ABL1—lymphoid tissue—skin cancer	0.000217	0.00138	CbGeAlD
Dasatinib—MAPK14—lymph node—skin cancer	0.000214	0.00136	CbGeAlD
Dasatinib—FGR—lymph node—skin cancer	0.000213	0.00136	CbGeAlD
Dasatinib—LCK—lymph node—skin cancer	0.000213	0.00136	CbGeAlD
Dasatinib—ABL1—female reproductive system—skin cancer	0.000209	0.00133	CbGeAlD
Dasatinib—FMO3—lymph node—skin cancer	0.000206	0.00131	CbGeAlD
Dasatinib—EPHB4—lymph node—skin cancer	0.000203	0.00129	CbGeAlD
Dasatinib—JAK2—lymph node—skin cancer	0.000201	0.00128	CbGeAlD
Dasatinib—KIT—head—skin cancer	0.000201	0.00128	CbGeAlD
Dasatinib—EPHA2—lymph node—skin cancer	0.000199	0.00127	CbGeAlD
Dasatinib—Flushing—Temozolomide—skin cancer	0.000199	0.001	CcSEcCtD
Dasatinib—FYN—lymph node—skin cancer	0.000199	0.00126	CbGeAlD
Dasatinib—Haemoglobin—Fluorouracil—skin cancer	0.000198	0.001	CcSEcCtD
Dasatinib—Haemorrhage—Fluorouracil—skin cancer	0.000197	0.000996	CcSEcCtD
Dasatinib—Dizziness—Vemurafenib—skin cancer	0.000197	0.000994	CcSEcCtD
Dasatinib—PDGFRB—head—skin cancer	0.000196	0.00125	CbGeAlD
Dasatinib—Angiopathy—Temozolomide—skin cancer	0.000194	0.000981	CcSEcCtD
Dasatinib—MAP3K3—lymph node—skin cancer	0.000194	0.00124	CbGeAlD
Dasatinib—MAP4K5—lymph node—skin cancer	0.000194	0.00124	CbGeAlD
Dasatinib—Immune system disorder—Temozolomide—skin cancer	0.000193	0.000977	CcSEcCtD
Dasatinib—Mediastinal disorder—Temozolomide—skin cancer	0.000193	0.000974	CcSEcCtD
Dasatinib—Cough—Bleomycin—skin cancer	0.000193	0.000974	CcSEcCtD
Dasatinib—Chills—Temozolomide—skin cancer	0.000192	0.00097	CcSEcCtD
Dasatinib—Ill-defined disorder—Dactinomycin—skin cancer	0.000191	0.000965	CcSEcCtD
Dasatinib—Anaemia—Dactinomycin—skin cancer	0.000191	0.000962	CcSEcCtD
Dasatinib—Vomiting—Vemurafenib—skin cancer	0.000189	0.000956	CcSEcCtD
Dasatinib—Alopecia—Temozolomide—skin cancer	0.000189	0.000955	CcSEcCtD
Dasatinib—Dry skin—Docetaxel—skin cancer	0.000189	0.000953	CcSEcCtD
Dasatinib—Chest pain—Bleomycin—skin cancer	0.000188	0.00095	CcSEcCtD
Dasatinib—Myalgia—Bleomycin—skin cancer	0.000188	0.00095	CcSEcCtD
Dasatinib—Rash—Vemurafenib—skin cancer	0.000188	0.000948	CcSEcCtD
Dasatinib—Mental disorder—Temozolomide—skin cancer	0.000188	0.000947	CcSEcCtD
Dasatinib—Dermatitis—Vemurafenib—skin cancer	0.000188	0.000947	CcSEcCtD
Dasatinib—Hypersensitivity—Imiquimod—skin cancer	0.000187	0.000944	CcSEcCtD
Dasatinib—Headache—Vemurafenib—skin cancer	0.000187	0.000942	CcSEcCtD
Dasatinib—Malnutrition—Temozolomide—skin cancer	0.000186	0.000941	CcSEcCtD
Dasatinib—Erythema—Temozolomide—skin cancer	0.000186	0.000941	CcSEcCtD
Dasatinib—Breast disorder—Docetaxel—skin cancer	0.000186	0.000939	CcSEcCtD
Dasatinib—Discomfort—Bleomycin—skin cancer	0.000186	0.000938	CcSEcCtD
Dasatinib—Malaise—Dactinomycin—skin cancer	0.000186	0.000938	CcSEcCtD
Dasatinib—EPHB6—lymph node—skin cancer	0.000185	0.00118	CbGeAlD
Dasatinib—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000185	0.000936	CcSEcCtD
Dasatinib—CYP1B1—lymphoid tissue—skin cancer	0.000184	0.00117	CbGeAlD
Dasatinib—Dysgeusia—Temozolomide—skin cancer	0.000183	0.000922	CcSEcCtD
Dasatinib—Asthenia—Imiquimod—skin cancer	0.000182	0.00092	CcSEcCtD
Dasatinib—Confusional state—Bleomycin—skin cancer	0.000182	0.000918	CcSEcCtD
Dasatinib—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000182	0.000917	CcSEcCtD
Dasatinib—Oedema—Bleomycin—skin cancer	0.00018	0.000911	CcSEcCtD
Dasatinib—ABCB1—blood vessel—skin cancer	0.00018	0.00115	CbGeAlD
Dasatinib—Pruritus—Imiquimod—skin cancer	0.00018	0.000907	CcSEcCtD
Dasatinib—Infection—Bleomycin—skin cancer	0.000179	0.000905	CcSEcCtD
Dasatinib—YES1—lymph node—skin cancer	0.000179	0.00114	CbGeAlD
Dasatinib—Dysphagia—Docetaxel—skin cancer	0.000178	0.000898	CcSEcCtD
Dasatinib—CYP1B1—female reproductive system—skin cancer	0.000177	0.00113	CbGeAlD
Dasatinib—Nausea—Vemurafenib—skin cancer	0.000177	0.000893	CcSEcCtD
Dasatinib—Thrombocytopenia—Bleomycin—skin cancer	0.000177	0.000892	CcSEcCtD
Dasatinib—Arrhythmia—Fluorouracil—skin cancer	0.000176	0.00089	CcSEcCtD
Dasatinib—PDGFRA—lymph node—skin cancer	0.000176	0.00112	CbGeAlD
Dasatinib—Vision blurred—Temozolomide—skin cancer	0.000176	0.000887	CcSEcCtD
Dasatinib—Myalgia—Dactinomycin—skin cancer	0.000175	0.000886	CcSEcCtD
Dasatinib—Bronchospasm—Docetaxel—skin cancer	0.000175	0.000884	CcSEcCtD
Dasatinib—ABL1—head—skin cancer	0.000175	0.00111	CbGeAlD
Dasatinib—Tremor—Temozolomide—skin cancer	0.000175	0.000882	CcSEcCtD
Dasatinib—Alopecia—Fluorouracil—skin cancer	0.000174	0.00088	CcSEcCtD
Dasatinib—Diarrhoea—Imiquimod—skin cancer	0.000174	0.000877	CcSEcCtD
Dasatinib—Discomfort—Dactinomycin—skin cancer	0.000173	0.000875	CcSEcCtD
Dasatinib—Angina pectoris—Docetaxel—skin cancer	0.000173	0.000875	CcSEcCtD
Dasatinib—Ill-defined disorder—Temozolomide—skin cancer	0.000173	0.000873	CcSEcCtD
Dasatinib—SRC—lymph node—skin cancer	0.000172	0.0011	CbGeAlD
Dasatinib—Anaemia—Temozolomide—skin cancer	0.000172	0.00087	CcSEcCtD
Dasatinib—Anorexia—Bleomycin—skin cancer	0.000172	0.000868	CcSEcCtD
Dasatinib—Erythema—Fluorouracil—skin cancer	0.000172	0.000867	CcSEcCtD
Dasatinib—Pancytopenia—Docetaxel—skin cancer	0.000169	0.000853	CcSEcCtD
Dasatinib—Hypotension—Bleomycin—skin cancer	0.000169	0.000851	CcSEcCtD
Dasatinib—CYP1A1—epithelium—skin cancer	0.000169	0.00107	CbGeAlD
Dasatinib—Oedema—Dactinomycin—skin cancer	0.000168	0.000849	CcSEcCtD
Dasatinib—Malaise—Temozolomide—skin cancer	0.000168	0.000849	CcSEcCtD
Dasatinib—Dizziness—Imiquimod—skin cancer	0.000168	0.000848	CcSEcCtD
Dasatinib—Vertigo—Temozolomide—skin cancer	0.000167	0.000846	CcSEcCtD
Dasatinib—Infection—Dactinomycin—skin cancer	0.000167	0.000844	CcSEcCtD
Dasatinib—Neutropenia—Docetaxel—skin cancer	0.000166	0.00084	CcSEcCtD
Dasatinib—Palpitations—Temozolomide—skin cancer	0.000165	0.000832	CcSEcCtD
Dasatinib—Thrombocytopenia—Dactinomycin—skin cancer	0.000165	0.000831	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000164	0.00083	CcSEcCtD
Dasatinib—Cough—Temozolomide—skin cancer	0.000163	0.000821	CcSEcCtD
Dasatinib—Weight increased—Docetaxel—skin cancer	0.000162	0.000817	CcSEcCtD
Dasatinib—Vision blurred—Fluorouracil—skin cancer	0.000162	0.000817	CcSEcCtD
Dasatinib—Convulsion—Temozolomide—skin cancer	0.000162	0.000815	CcSEcCtD
Dasatinib—Vomiting—Imiquimod—skin cancer	0.000161	0.000815	CcSEcCtD
Dasatinib—Weight decreased—Docetaxel—skin cancer	0.000161	0.000813	CcSEcCtD
Dasatinib—Hypertension—Temozolomide—skin cancer	0.000161	0.000813	CcSEcCtD
Dasatinib—Dyspnoea—Bleomycin—skin cancer	0.000161	0.000812	CcSEcCtD
Dasatinib—Anorexia—Dactinomycin—skin cancer	0.00016	0.000809	CcSEcCtD
Dasatinib—CYP1A1—skin of body—skin cancer	0.00016	0.00102	CbGeAlD
Dasatinib—Rash—Imiquimod—skin cancer	0.00016	0.000808	CcSEcCtD
Dasatinib—Dermatitis—Imiquimod—skin cancer	0.00016	0.000807	CcSEcCtD
Dasatinib—Pneumonia—Docetaxel—skin cancer	0.00016	0.000806	CcSEcCtD
Dasatinib—Headache—Imiquimod—skin cancer	0.000159	0.000803	CcSEcCtD
Dasatinib—Anaemia—Fluorouracil—skin cancer	0.000159	0.000801	CcSEcCtD
Dasatinib—Myalgia—Temozolomide—skin cancer	0.000159	0.000801	CcSEcCtD
Dasatinib—Arthralgia—Temozolomide—skin cancer	0.000159	0.000801	CcSEcCtD
Dasatinib—Infestation NOS—Docetaxel—skin cancer	0.000159	0.000801	CcSEcCtD
Dasatinib—Infestation—Docetaxel—skin cancer	0.000159	0.000801	CcSEcCtD
Dasatinib—MAP2K5—lymph node—skin cancer	0.000159	0.00101	CbGeAlD
Dasatinib—Anxiety—Temozolomide—skin cancer	0.000158	0.000798	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000158	0.000796	CcSEcCtD
Dasatinib—Discomfort—Temozolomide—skin cancer	0.000157	0.000792	CcSEcCtD
Dasatinib—Decreased appetite—Bleomycin—skin cancer	0.000157	0.000792	CcSEcCtD
Dasatinib—Acute coronary syndrome—Docetaxel—skin cancer	0.000156	0.000789	CcSEcCtD
Dasatinib—Renal failure—Docetaxel—skin cancer	0.000156	0.000787	CcSEcCtD
Dasatinib—Neuropathy peripheral—Docetaxel—skin cancer	0.000156	0.000785	CcSEcCtD
Dasatinib—Myocardial infarction—Docetaxel—skin cancer	0.000156	0.000785	CcSEcCtD
Dasatinib—CSF1R—lymph node—skin cancer	0.000155	0.000985	CbGeAlD
Dasatinib—Stomatitis—Docetaxel—skin cancer	0.000155	0.000781	CcSEcCtD
Dasatinib—Pain—Bleomycin—skin cancer	0.000154	0.000779	CcSEcCtD
Dasatinib—Conjunctivitis—Docetaxel—skin cancer	0.000154	0.000778	CcSEcCtD
Dasatinib—ABCG2—mammalian vulva—skin cancer	0.000154	0.00098	CbGeAlD
Dasatinib—Confusional state—Temozolomide—skin cancer	0.000153	0.000774	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000153	0.000774	CcSEcCtD
Dasatinib—Oedema—Temozolomide—skin cancer	0.000152	0.000768	CcSEcCtD
Dasatinib—Infection—Temozolomide—skin cancer	0.000151	0.000763	CcSEcCtD
Dasatinib—Nausea—Imiquimod—skin cancer	0.000151	0.000761	CcSEcCtD
Dasatinib—Hepatobiliary disease—Docetaxel—skin cancer	0.00015	0.000757	CcSEcCtD
Dasatinib—Epistaxis—Docetaxel—skin cancer	0.00015	0.000755	CcSEcCtD
Dasatinib—Nervous system disorder—Temozolomide—skin cancer	0.000149	0.000753	CcSEcCtD
Dasatinib—Thrombocytopenia—Temozolomide—skin cancer	0.000149	0.000752	CcSEcCtD
Dasatinib—Convulsion—Fluorouracil—skin cancer	0.000149	0.000751	CcSEcCtD
Dasatinib—Feeling abnormal—Bleomycin—skin cancer	0.000149	0.00075	CcSEcCtD
Dasatinib—CYP1B1—head—skin cancer	0.000148	0.000942	CbGeAlD
Dasatinib—Skin disorder—Temozolomide—skin cancer	0.000148	0.000746	CcSEcCtD
Dasatinib—Hyperhidrosis—Temozolomide—skin cancer	0.000147	0.000743	CcSEcCtD
Dasatinib—Chest pain—Fluorouracil—skin cancer	0.000146	0.000738	CcSEcCtD
Dasatinib—Myalgia—Fluorouracil—skin cancer	0.000146	0.000738	CcSEcCtD
Dasatinib—Decreased appetite—Dactinomycin—skin cancer	0.000146	0.000738	CcSEcCtD
Dasatinib—CYP1A1—mammalian vulva—skin cancer	0.000146	0.000931	CbGeAlD
Dasatinib—Fatigue—Dactinomycin—skin cancer	0.000145	0.000732	CcSEcCtD
Dasatinib—Anorexia—Temozolomide—skin cancer	0.000145	0.000732	CcSEcCtD
Dasatinib—Discomfort—Fluorouracil—skin cancer	0.000144	0.000729	CcSEcCtD
Dasatinib—Pain—Dactinomycin—skin cancer	0.000144	0.000726	CcSEcCtD
Dasatinib—Urticaria—Bleomycin—skin cancer	0.000143	0.000723	CcSEcCtD
Dasatinib—Haemoglobin—Docetaxel—skin cancer	0.000143	0.000723	CcSEcCtD
Dasatinib—Body temperature increased—Bleomycin—skin cancer	0.000143	0.00072	CcSEcCtD
Dasatinib—Hepatitis—Docetaxel—skin cancer	0.000142	0.000719	CcSEcCtD
Dasatinib—Haemorrhage—Docetaxel—skin cancer	0.000142	0.000719	CcSEcCtD
Dasatinib—Confusional state—Fluorouracil—skin cancer	0.000141	0.000714	CcSEcCtD
Dasatinib—Urinary tract disorder—Docetaxel—skin cancer	0.000141	0.00071	CcSEcCtD
Dasatinib—KIT—lymph node—skin cancer	0.000141	0.000895	CbGeAlD
Dasatinib—Oedema peripheral—Docetaxel—skin cancer	0.00014	0.000708	CcSEcCtD
Dasatinib—Oedema—Fluorouracil—skin cancer	0.00014	0.000708	CcSEcCtD
Dasatinib—Connective tissue disorder—Docetaxel—skin cancer	0.00014	0.000706	CcSEcCtD
Dasatinib—Urethral disorder—Docetaxel—skin cancer	0.00014	0.000705	CcSEcCtD
Dasatinib—Infection—Fluorouracil—skin cancer	0.000139	0.000703	CcSEcCtD
Dasatinib—Feeling abnormal—Dactinomycin—skin cancer	0.000139	0.0007	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000139	0.0007	CcSEcCtD
Dasatinib—Insomnia—Temozolomide—skin cancer	0.000138	0.000695	CcSEcCtD
Dasatinib—Gastrointestinal pain—Dactinomycin—skin cancer	0.000138	0.000694	CcSEcCtD
Dasatinib—Nervous system disorder—Fluorouracil—skin cancer	0.000137	0.000694	CcSEcCtD
Dasatinib—Thrombocytopenia—Fluorouracil—skin cancer	0.000137	0.000693	CcSEcCtD
Dasatinib—Visual impairment—Docetaxel—skin cancer	0.000137	0.000693	CcSEcCtD
Dasatinib—PDGFRB—lymph node—skin cancer	0.000137	0.000874	CbGeAlD
Dasatinib—Tachycardia—Fluorouracil—skin cancer	0.000137	0.000691	CcSEcCtD
Dasatinib—Dyspnoea—Temozolomide—skin cancer	0.000136	0.000685	CcSEcCtD
Dasatinib—Somnolence—Temozolomide—skin cancer	0.000135	0.000683	CcSEcCtD
Dasatinib—Erythema multiforme—Docetaxel—skin cancer	0.000135	0.00068	CcSEcCtD
Dasatinib—Dyspepsia—Temozolomide—skin cancer	0.000134	0.000676	CcSEcCtD
Dasatinib—Anorexia—Fluorouracil—skin cancer	0.000134	0.000675	CcSEcCtD
Dasatinib—Eye disorder—Docetaxel—skin cancer	0.000133	0.000672	CcSEcCtD
Dasatinib—Body temperature increased—Dactinomycin—skin cancer	0.000133	0.000671	CcSEcCtD
Dasatinib—Abdominal pain—Dactinomycin—skin cancer	0.000133	0.000671	CcSEcCtD
Dasatinib—Hypersensitivity—Bleomycin—skin cancer	0.000133	0.000671	CcSEcCtD
Dasatinib—Decreased appetite—Temozolomide—skin cancer	0.000132	0.000668	CcSEcCtD
Dasatinib—Cardiac disorder—Docetaxel—skin cancer	0.000132	0.000667	CcSEcCtD
Dasatinib—Flushing—Docetaxel—skin cancer	0.000132	0.000667	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Temozolomide—skin cancer	0.000131	0.000663	CcSEcCtD
Dasatinib—Fatigue—Temozolomide—skin cancer	0.000131	0.000662	CcSEcCtD
Dasatinib—Hypotension—Fluorouracil—skin cancer	0.000131	0.000661	CcSEcCtD
Dasatinib—Constipation—Temozolomide—skin cancer	0.00013	0.000657	CcSEcCtD
Dasatinib—Pain—Temozolomide—skin cancer	0.00013	0.000657	CcSEcCtD
Dasatinib—Asthenia—Bleomycin—skin cancer	0.000129	0.000653	CcSEcCtD
Dasatinib—Angiopathy—Docetaxel—skin cancer	0.000129	0.000652	CcSEcCtD
Dasatinib—Immune system disorder—Docetaxel—skin cancer	0.000129	0.000649	CcSEcCtD
Dasatinib—Mediastinal disorder—Docetaxel—skin cancer	0.000128	0.000648	CcSEcCtD
Dasatinib—Chills—Docetaxel—skin cancer	0.000128	0.000645	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000128	0.000645	CcSEcCtD
Dasatinib—Pruritus—Bleomycin—skin cancer	0.000128	0.000644	CcSEcCtD
Dasatinib—Arrhythmia—Docetaxel—skin cancer	0.000127	0.000642	CcSEcCtD
Dasatinib—Insomnia—Fluorouracil—skin cancer	0.000127	0.00064	CcSEcCtD
Dasatinib—Alopecia—Docetaxel—skin cancer	0.000126	0.000635	CcSEcCtD
Dasatinib—Feeling abnormal—Temozolomide—skin cancer	0.000125	0.000633	CcSEcCtD
Dasatinib—CYP1A1—female reproductive system—skin cancer	0.000125	0.000797	CbGeAlD
Dasatinib—Dyspnoea—Fluorouracil—skin cancer	0.000125	0.000631	CcSEcCtD
Dasatinib—Mental disorder—Docetaxel—skin cancer	0.000125	0.00063	CcSEcCtD
Dasatinib—Somnolence—Fluorouracil—skin cancer	0.000125	0.000629	CcSEcCtD
Dasatinib—Gastrointestinal pain—Temozolomide—skin cancer	0.000124	0.000628	CcSEcCtD
Dasatinib—Malnutrition—Docetaxel—skin cancer	0.000124	0.000626	CcSEcCtD
Dasatinib—Erythema—Docetaxel—skin cancer	0.000124	0.000626	CcSEcCtD
Dasatinib—Hypersensitivity—Dactinomycin—skin cancer	0.000124	0.000626	CcSEcCtD
Dasatinib—Dyspepsia—Fluorouracil—skin cancer	0.000123	0.000623	CcSEcCtD
Dasatinib—ABL1—lymph node—skin cancer	0.000122	0.000779	CbGeAlD
Dasatinib—Decreased appetite—Fluorouracil—skin cancer	0.000122	0.000615	CcSEcCtD
Dasatinib—Dysgeusia—Docetaxel—skin cancer	0.000121	0.000613	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000121	0.000611	CcSEcCtD
Dasatinib—Urticaria—Temozolomide—skin cancer	0.000121	0.00061	CcSEcCtD
Dasatinib—Asthenia—Dactinomycin—skin cancer	0.000121	0.000609	CcSEcCtD
Dasatinib—Body temperature increased—Temozolomide—skin cancer	0.00012	0.000607	CcSEcCtD
Dasatinib—Abdominal pain—Temozolomide—skin cancer	0.00012	0.000607	CcSEcCtD
Dasatinib—Pain—Fluorouracil—skin cancer	0.00012	0.000605	CcSEcCtD
Dasatinib—Muscle spasms—Docetaxel—skin cancer	0.000119	0.000602	CcSEcCtD
Dasatinib—Feeling abnormal—Fluorouracil—skin cancer	0.000116	0.000583	CcSEcCtD
Dasatinib—Diarrhoea—Dactinomycin—skin cancer	0.000115	0.000581	CcSEcCtD
Dasatinib—Vomiting—Bleomycin—skin cancer	0.000115	0.000579	CcSEcCtD
Dasatinib—Anaemia—Docetaxel—skin cancer	0.000115	0.000578	CcSEcCtD
Dasatinib—Rash—Bleomycin—skin cancer	0.000114	0.000574	CcSEcCtD
Dasatinib—Dermatitis—Bleomycin—skin cancer	0.000114	0.000574	CcSEcCtD
Dasatinib—Hypersensitivity—Temozolomide—skin cancer	0.000112	0.000566	CcSEcCtD
Dasatinib—Urticaria—Fluorouracil—skin cancer	0.000111	0.000562	CcSEcCtD
Dasatinib—Syncope—Docetaxel—skin cancer	0.000111	0.000561	CcSEcCtD
Dasatinib—Body temperature increased—Fluorouracil—skin cancer	0.000111	0.000559	CcSEcCtD
Dasatinib—Palpitations—Docetaxel—skin cancer	0.00011	0.000553	CcSEcCtD
Dasatinib—Asthenia—Temozolomide—skin cancer	0.000109	0.000551	CcSEcCtD
Dasatinib—Loss of consciousness—Docetaxel—skin cancer	0.000109	0.00055	CcSEcCtD
Dasatinib—Cough—Docetaxel—skin cancer	0.000108	0.000546	CcSEcCtD
Dasatinib—Pruritus—Temozolomide—skin cancer	0.000108	0.000543	CcSEcCtD
Dasatinib—Convulsion—Docetaxel—skin cancer	0.000107	0.000542	CcSEcCtD
Dasatinib—Nausea—Bleomycin—skin cancer	0.000107	0.000541	CcSEcCtD
Dasatinib—Hypertension—Docetaxel—skin cancer	0.000107	0.00054	CcSEcCtD
Dasatinib—Vomiting—Dactinomycin—skin cancer	0.000107	0.00054	CcSEcCtD
Dasatinib—Rash—Dactinomycin—skin cancer	0.000106	0.000535	CcSEcCtD
Dasatinib—Chest pain—Docetaxel—skin cancer	0.000106	0.000533	CcSEcCtD
Dasatinib—Arthralgia—Docetaxel—skin cancer	0.000106	0.000533	CcSEcCtD
Dasatinib—Myalgia—Docetaxel—skin cancer	0.000106	0.000533	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000105	0.000529	CcSEcCtD
Dasatinib—CYP1A1—head—skin cancer	0.000105	0.000666	CbGeAlD
Dasatinib—Diarrhoea—Temozolomide—skin cancer	0.000104	0.000526	CcSEcCtD
Dasatinib—CYP1B1—lymph node—skin cancer	0.000104	0.00066	CbGeAlD
Dasatinib—Hypersensitivity—Fluorouracil—skin cancer	0.000103	0.000521	CcSEcCtD
Dasatinib—Confusional state—Docetaxel—skin cancer	0.000102	0.000515	CcSEcCtD
Dasatinib—Oedema—Docetaxel—skin cancer	0.000101	0.000511	CcSEcCtD
Dasatinib—Dizziness—Temozolomide—skin cancer	0.000101	0.000508	CcSEcCtD
Dasatinib—Infection—Docetaxel—skin cancer	0.000101	0.000507	CcSEcCtD
Dasatinib—Nausea—Dactinomycin—skin cancer	9.99e-05	0.000504	CcSEcCtD
Dasatinib—Shock—Docetaxel—skin cancer	9.95e-05	0.000503	CcSEcCtD
Dasatinib—Nervous system disorder—Docetaxel—skin cancer	9.92e-05	0.000501	CcSEcCtD
Dasatinib—Pruritus—Fluorouracil—skin cancer	9.92e-05	0.000501	CcSEcCtD
Dasatinib—Thrombocytopenia—Docetaxel—skin cancer	9.91e-05	0.0005	CcSEcCtD
Dasatinib—Tachycardia—Docetaxel—skin cancer	9.88e-05	0.000499	CcSEcCtD
Dasatinib—Skin disorder—Docetaxel—skin cancer	9.83e-05	0.000496	CcSEcCtD
Dasatinib—Vomiting—Temozolomide—skin cancer	9.67e-05	0.000488	CcSEcCtD
Dasatinib—Anorexia—Docetaxel—skin cancer	9.65e-05	0.000487	CcSEcCtD
Dasatinib—Rash—Temozolomide—skin cancer	9.59e-05	0.000484	CcSEcCtD
Dasatinib—Diarrhoea—Fluorouracil—skin cancer	9.59e-05	0.000484	CcSEcCtD
Dasatinib—Dermatitis—Temozolomide—skin cancer	9.58e-05	0.000484	CcSEcCtD
Dasatinib—Headache—Temozolomide—skin cancer	9.53e-05	0.000481	CcSEcCtD
Dasatinib—Hypotension—Docetaxel—skin cancer	9.46e-05	0.000477	CcSEcCtD
Dasatinib—Dizziness—Fluorouracil—skin cancer	9.27e-05	0.000468	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Docetaxel—skin cancer	9.22e-05	0.000465	CcSEcCtD
Dasatinib—CYP3A4—female reproductive system—skin cancer	9.19e-05	0.000585	CbGeAlD
Dasatinib—Insomnia—Docetaxel—skin cancer	9.15e-05	0.000462	CcSEcCtD
Dasatinib—Nausea—Temozolomide—skin cancer	9.04e-05	0.000456	CcSEcCtD
Dasatinib—Dyspnoea—Docetaxel—skin cancer	9.02e-05	0.000455	CcSEcCtD
Dasatinib—Somnolence—Docetaxel—skin cancer	9e-05	0.000454	CcSEcCtD
Dasatinib—Vomiting—Fluorouracil—skin cancer	8.91e-05	0.00045	CcSEcCtD
Dasatinib—Dyspepsia—Docetaxel—skin cancer	8.91e-05	0.00045	CcSEcCtD
Dasatinib—Rash—Fluorouracil—skin cancer	8.84e-05	0.000446	CcSEcCtD
Dasatinib—Dermatitis—Fluorouracil—skin cancer	8.83e-05	0.000446	CcSEcCtD
Dasatinib—Decreased appetite—Docetaxel—skin cancer	8.8e-05	0.000444	CcSEcCtD
Dasatinib—Headache—Fluorouracil—skin cancer	8.78e-05	0.000443	CcSEcCtD
Dasatinib—ABCB1—epithelium—skin cancer	8.75e-05	0.000557	CbGeAlD
Dasatinib—Gastrointestinal disorder—Docetaxel—skin cancer	8.74e-05	0.000441	CcSEcCtD
Dasatinib—Fatigue—Docetaxel—skin cancer	8.72e-05	0.00044	CcSEcCtD
Dasatinib—Constipation—Docetaxel—skin cancer	8.65e-05	0.000437	CcSEcCtD
Dasatinib—Pain—Docetaxel—skin cancer	8.65e-05	0.000437	CcSEcCtD
Dasatinib—Feeling abnormal—Docetaxel—skin cancer	8.34e-05	0.000421	CcSEcCtD
Dasatinib—Nausea—Fluorouracil—skin cancer	8.33e-05	0.00042	CcSEcCtD
Dasatinib—Gastrointestinal pain—Docetaxel—skin cancer	8.27e-05	0.000418	CcSEcCtD
Dasatinib—Abdominal pain—Docetaxel—skin cancer	8e-05	0.000404	CcSEcCtD
Dasatinib—Body temperature increased—Docetaxel—skin cancer	8e-05	0.000404	CcSEcCtD
Dasatinib—ABCG2—lymph node—skin cancer	7.71e-05	0.000491	CbGeAlD
Dasatinib—ABCB1—mammalian vulva—skin cancer	7.59e-05	0.000483	CbGeAlD
Dasatinib—Hypersensitivity—Docetaxel—skin cancer	7.45e-05	0.000376	CcSEcCtD
Dasatinib—CYP1A1—lymph node—skin cancer	7.32e-05	0.000466	CbGeAlD
Dasatinib—Asthenia—Docetaxel—skin cancer	7.26e-05	0.000366	CcSEcCtD
Dasatinib—Pruritus—Docetaxel—skin cancer	7.16e-05	0.000361	CcSEcCtD
Dasatinib—Diarrhoea—Docetaxel—skin cancer	6.92e-05	0.000349	CcSEcCtD
Dasatinib—ABCB1—lymphoid tissue—skin cancer	6.74e-05	0.000429	CbGeAlD
Dasatinib—Dizziness—Docetaxel—skin cancer	6.69e-05	0.000338	CcSEcCtD
Dasatinib—ABCB1—female reproductive system—skin cancer	6.5e-05	0.000414	CbGeAlD
Dasatinib—Vomiting—Docetaxel—skin cancer	6.43e-05	0.000325	CcSEcCtD
Dasatinib—Rash—Docetaxel—skin cancer	6.38e-05	0.000322	CcSEcCtD
Dasatinib—Dermatitis—Docetaxel—skin cancer	6.37e-05	0.000322	CcSEcCtD
Dasatinib—Headache—Docetaxel—skin cancer	6.34e-05	0.00032	CcSEcCtD
Dasatinib—Nausea—Docetaxel—skin cancer	6.01e-05	0.000303	CcSEcCtD
Dasatinib—ABCB1—head—skin cancer	5.43e-05	0.000346	CbGeAlD
Dasatinib—ABCB1—lymph node—skin cancer	3.8e-05	0.000242	CbGeAlD
Dasatinib—HCK—Immune System—HRAS—skin cancer	5.94e-06	2.94e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—KRAS—skin cancer	5.93e-06	2.94e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—PTGS2—skin cancer	5.93e-06	2.94e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—NRAS—skin cancer	5.92e-06	2.93e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—IL6—skin cancer	5.91e-06	2.93e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—KRAS—skin cancer	5.88e-06	2.91e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—HRAS—skin cancer	5.87e-06	2.91e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TERT—skin cancer	5.85e-06	2.9e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—HRAS—skin cancer	5.83e-06	2.89e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—ERCC2—skin cancer	5.81e-06	2.87e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—KRAS—skin cancer	5.8e-06	2.87e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—HRAS—skin cancer	5.76e-06	2.85e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TERT—skin cancer	5.73e-06	2.84e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—KRAS—skin cancer	5.7e-06	2.82e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—IL6—skin cancer	5.69e-06	2.82e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—IL6—skin cancer	5.68e-06	2.81e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—HRAS—skin cancer	5.66e-06	2.8e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TERT—skin cancer	5.64e-06	2.79e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—IL6—skin cancer	5.62e-06	2.78e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—HRAS—skin cancer	5.59e-06	2.77e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—HRAS—skin cancer	5.54e-06	2.74e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—HRAS—skin cancer	5.52e-06	2.73e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—NRAS—skin cancer	5.5e-06	2.72e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—HRAS—skin cancer	5.48e-06	2.71e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—HRAS—skin cancer	5.45e-06	2.7e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—BRAF—skin cancer	5.44e-06	2.69e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—HRAS—skin cancer	5.43e-06	2.69e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TERT—skin cancer	5.43e-06	2.69e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—IL6—skin cancer	5.42e-06	2.68e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ENO2—skin cancer	5.4e-06	2.68e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—HRAS—skin cancer	5.38e-06	2.66e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TERT—skin cancer	5.36e-06	2.65e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—HRAS—skin cancer	5.36e-06	2.65e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—KRAS—skin cancer	5.36e-06	2.65e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—KRAS—skin cancer	5.36e-06	2.65e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—IL6—skin cancer	5.35e-06	2.65e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PTGS2—skin cancer	5.35e-06	2.65e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—KRAS—skin cancer	5.34e-06	2.65e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—HRAS—skin cancer	5.32e-06	2.63e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—BRAF—skin cancer	5.31e-06	2.63e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—IL6—skin cancer	5.3e-06	2.63e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.29e-06	2.62e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—NRAS—skin cancer	5.28e-06	2.62e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—IL6—skin cancer	5.28e-06	2.61e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—NRAS—skin cancer	5.28e-06	2.61e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—skin cancer	5.27e-06	2.61e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—KRAS—skin cancer	5.25e-06	2.6e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—HRAS—skin cancer	5.25e-06	2.6e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—IL6—skin cancer	5.25e-06	2.6e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—HRAS—skin cancer	5.24e-06	2.59e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—skin cancer	5.23e-06	2.59e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—IL6—skin cancer	5.22e-06	2.58e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—HRAS—skin cancer	5.19e-06	2.57e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—PTGS2—skin cancer	5.15e-06	2.55e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—IL6—skin cancer	5.15e-06	2.55e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—BRAF—skin cancer	5.14e-06	2.55e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—IL6—skin cancer	5.13e-06	2.54e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—KRAS—skin cancer	5.13e-06	2.54e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—KRAS—skin cancer	5.09e-06	2.52e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—skin cancer	5.06e-06	2.51e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—HRAS—skin cancer	5.04e-06	2.5e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—IL6—skin cancer	5.03e-06	2.49e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—HRAS—skin cancer	5e-06	2.48e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—NRAS—skin cancer	5e-06	2.48e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—IL6—skin cancer	4.96e-06	2.46e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—NRAS—skin cancer	4.94e-06	2.45e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—HRAS—skin cancer	4.93e-06	2.44e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—PTGS2—skin cancer	4.9e-06	2.43e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CSPG4—skin cancer	4.9e-06	2.42e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—NRAS—skin cancer	4.88e-06	2.41e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—HRAS—skin cancer	4.84e-06	2.4e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—IL6—skin cancer	4.79e-06	2.37e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—KRAS—skin cancer	4.73e-06	2.34e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—IL6—skin cancer	4.72e-06	2.34e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—BRAF—skin cancer	4.7e-06	2.33e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TERT—skin cancer	4.7e-06	2.33e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—skin cancer	4.67e-06	2.31e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—IL6—skin cancer	4.64e-06	2.3e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—BRAF—skin cancer	4.64e-06	2.29e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—NRAS—skin cancer	4.62e-06	2.29e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—HRAS—skin cancer	4.55e-06	2.25e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—HRAS—skin cancer	4.55e-06	2.25e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—KRAS—skin cancer	4.55e-06	2.25e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—KRAS—skin cancer	4.54e-06	2.25e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—HRAS—skin cancer	4.54e-06	2.25e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—BRAF—skin cancer	4.54e-06	2.25e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—NRAS—skin cancer	4.52e-06	2.24e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—NRAS—skin cancer	4.52e-06	2.24e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—NRAS—skin cancer	4.51e-06	2.23e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—BRAF—skin cancer	4.47e-06	2.21e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—HRAS—skin cancer	4.47e-06	2.21e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—NRAS—skin cancer	4.41e-06	2.18e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—NRAS—skin cancer	4.39e-06	2.17e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—HRAS—skin cancer	4.36e-06	2.16e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—NRAS—skin cancer	4.36e-06	2.16e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—IL6—skin cancer	4.36e-06	2.16e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—IL6—skin cancer	4.36e-06	2.16e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—IL6—skin cancer	4.35e-06	2.15e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—NRAS—skin cancer	4.34e-06	2.15e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—HRAS—skin cancer	4.33e-06	2.14e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ENO2—skin cancer	4.31e-06	2.14e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—KRAS—skin cancer	4.3e-06	2.13e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—BRAF—skin cancer	4.3e-06	2.13e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—PTGS2—skin cancer	4.29e-06	2.12e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—KRAS—skin cancer	4.25e-06	2.11e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—BRAF—skin cancer	4.25e-06	2.1e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—KRAS—skin cancer	4.2e-06	2.08e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—NRAS—skin cancer	4.18e-06	2.07e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NRAS—skin cancer	4.16e-06	2.06e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ERCC2—skin cancer	4.16e-06	2.06e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TERT—skin cancer	4.16e-06	2.06e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—IL6—skin cancer	4.14e-06	2.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—NRAS—skin cancer	4.13e-06	2.04e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—HRAS—skin cancer	4.02e-06	1.99e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—NRAS—skin cancer	4.01e-06	1.99e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—KRAS—skin cancer	3.97e-06	1.97e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ERCC2—skin cancer	3.93e-06	1.95e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—KRAS—skin cancer	3.89e-06	1.93e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—KRAS—skin cancer	3.89e-06	1.93e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—KRAS—skin cancer	3.88e-06	1.92e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—HRAS—skin cancer	3.87e-06	1.91e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—HRAS—skin cancer	3.86e-06	1.91e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—IL6—skin cancer	3.85e-06	1.91e-05	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTGS2—skin cancer	3.83e-06	1.89e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NRAS—skin cancer	3.82e-06	1.89e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NRAS—skin cancer	3.81e-06	1.89e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—PTGS2—skin cancer	3.8e-06	1.88e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—KRAS—skin cancer	3.8e-06	1.88e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—skin cancer	3.78e-06	1.87e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KRAS—skin cancer	3.78e-06	1.87e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KRAS—skin cancer	3.75e-06	1.86e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—KRAS—skin cancer	3.74e-06	1.85e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—BRAF—skin cancer	3.72e-06	1.84e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—IL6—skin cancer	3.7e-06	1.83e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—skin cancer	3.66e-06	1.81e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—skin cancer	3.62e-06	1.79e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—NRAS—skin cancer	3.62e-06	1.79e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KRAS—skin cancer	3.6e-06	1.78e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KRAS—skin cancer	3.58e-06	1.77e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—skin cancer	3.57e-06	1.77e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KRAS—skin cancer	3.55e-06	1.76e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL6—skin cancer	3.5e-06	1.73e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—skin cancer	3.48e-06	1.72e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—skin cancer	3.46e-06	1.71e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—skin cancer	3.46e-06	1.71e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—KRAS—skin cancer	3.45e-06	1.71e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NRAS—skin cancer	3.42e-06	1.69e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—skin cancer	3.42e-06	1.69e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—skin cancer	3.38e-06	1.67e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.37e-06	1.67e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NRAS—skin cancer	3.34e-06	1.65e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—skin cancer	3.33e-06	1.65e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ENO2—skin cancer	3.33e-06	1.65e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—skin cancer	3.31e-06	1.64e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—skin cancer	3.31e-06	1.64e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—skin cancer	3.3e-06	1.63e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—BRAF—skin cancer	3.29e-06	1.63e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—skin cancer	3.29e-06	1.63e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—skin cancer	3.28e-06	1.62e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NRAS—skin cancer	3.23e-06	1.6e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—skin cancer	3.23e-06	1.6e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—skin cancer	3.23e-06	1.6e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—skin cancer	3.21e-06	1.59e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—NRAS—skin cancer	3.2e-06	1.58e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—skin cancer	3.19e-06	1.58e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—skin cancer	3.18e-06	1.57e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—skin cancer	3.17e-06	1.57e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—skin cancer	3.16e-06	1.57e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—skin cancer	3.15e-06	1.56e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ERCC2—skin cancer	3.14e-06	1.55e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—skin cancer	3.11e-06	1.54e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—skin cancer	3.09e-06	1.53e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—skin cancer	3.07e-06	1.52e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—skin cancer	3.06e-06	1.51e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—skin cancer	3.05e-06	1.51e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—skin cancer	3.04e-06	1.51e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—skin cancer	3.04e-06	1.51e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—skin cancer	3.02e-06	1.5e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—skin cancer	2.96e-06	1.46e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—skin cancer	2.94e-06	1.46e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—skin cancer	2.93e-06	1.45e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—skin cancer	2.93e-06	1.45e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—skin cancer	2.93e-06	1.45e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—skin cancer	2.91e-06	1.44e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—skin cancer	2.91e-06	1.44e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—skin cancer	2.89e-06	1.43e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—skin cancer	2.87e-06	1.42e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—skin cancer	2.85e-06	1.41e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—skin cancer	2.81e-06	1.39e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—skin cancer	2.81e-06	1.39e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—skin cancer	2.8e-06	1.39e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—skin cancer	2.79e-06	1.38e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—skin cancer	2.78e-06	1.38e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—skin cancer	2.75e-06	1.36e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—skin cancer	2.7e-06	1.34e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—skin cancer	2.68e-06	1.33e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—skin cancer	2.67e-06	1.32e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—skin cancer	2.67e-06	1.32e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—skin cancer	2.65e-06	1.31e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—skin cancer	2.61e-06	1.29e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—skin cancer	2.54e-06	1.26e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—skin cancer	2.53e-06	1.25e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—skin cancer	2.51e-06	1.24e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ERCC2—skin cancer	2.51e-06	1.24e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—skin cancer	2.5e-06	1.24e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—skin cancer	2.49e-06	1.23e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—skin cancer	2.47e-06	1.22e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—skin cancer	2.45e-06	1.22e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—skin cancer	2.44e-06	1.21e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—skin cancer	2.42e-06	1.2e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—skin cancer	2.39e-06	1.18e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—skin cancer	2.37e-06	1.17e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—skin cancer	2.36e-06	1.17e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—skin cancer	2.34e-06	1.16e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—skin cancer	2.34e-06	1.16e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—skin cancer	2.34e-06	1.16e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—skin cancer	2.33e-06	1.15e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—skin cancer	2.3e-06	1.14e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—skin cancer	2.26e-06	1.12e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—skin cancer	2.24e-06	1.11e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—skin cancer	2.23e-06	1.1e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—skin cancer	2.18e-06	1.08e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—skin cancer	2.16e-06	1.07e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—skin cancer	2.15e-06	1.06e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—skin cancer	2.13e-06	1.06e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—skin cancer	2.09e-06	1.03e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—skin cancer	2.07e-06	1.02e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—skin cancer	2.07e-06	1.02e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—skin cancer	2.07e-06	1.02e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—skin cancer	2.05e-06	1.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—skin cancer	2.04e-06	1.01e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—skin cancer	2.04e-06	1.01e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—skin cancer	2.01e-06	9.96e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—skin cancer	2e-06	9.89e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—skin cancer	1.98e-06	9.79e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—skin cancer	1.97e-06	9.73e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—skin cancer	1.95e-06	9.67e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ERCC2—skin cancer	1.93e-06	9.57e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—skin cancer	1.89e-06	9.37e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—skin cancer	1.88e-06	9.32e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—skin cancer	1.87e-06	9.25e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—skin cancer	1.79e-06	8.85e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—skin cancer	1.78e-06	8.82e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—skin cancer	1.71e-06	8.47e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—skin cancer	1.64e-06	8.1e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—skin cancer	1.58e-06	7.84e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—skin cancer	1.51e-06	7.5e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—skin cancer	1.5e-06	7.44e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—skin cancer	1.45e-06	7.17e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—skin cancer	1.16e-06	5.74e-06	CbGpPWpGaD
